DPP 4 INHIBITORS: A NEW ERA OF TREATING TYPE 2 DIABETES MELLITUS
Jadav H*, Lad K, Jadav P
Journal Title:World Journal of Pharmaceutical Research
Type 2 diabetes is a complex metabolic disorder, comprising altered
insulin sensitivity and impaired insulin secretion. Now-a-days various
treatments are available for the treatment of type 2 diabetes mellitus.
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for
type-2 diabetes. In recent years, various DPP-4 inhibitors have been
released as therapeutic drugs for type 2 diabetes. These agents inhibit
thedegradation of the incretins glucagon -like peptide-1 (GLP-1) and
glucose-dependent insulinotropicpolypeptide (GIP) and hence
potentiate glucose-dependent insulin secretion.They are well-tolerated
with no weight gain and few adverse effects, and, of particular interest,
no increase in hypoglycemic episodes.DPP-4 inhibition is suggested to be a first-line
treatment of type-2 diabetes, particularly in its early stages in combination with metformin.
Several DPP-4 inhibitors are in clinical development, and many are already available in the
market like sitagliptin, vildagliptinetc. some of them have patents for chemical entities for
inhibiting DPP 4 enzyme in vitro and in vivo. However, further studies are needed to validate
both longtermb-cell preservation and the role of these agents in the management of
diabetes.The present review gives an inside out of the DPP IV inhibitors, novel drugs in
clinical trials, patents and combination therapy with other anti diabetic drugs.